Latissimus Dorsi Activity During Different Exercises (L-DORSI-EMG)

December 22, 2025 updated by: Irem Duzgun, Hacettepe University

Investigation of Latissimus Dorsi Muscle Activation During Different Exercises

This single-visit, laboratory study will quantify latissimus dorsi activation during standardized band/body-weight exercises commonly used in rehabilitation (e.g., standing bent-over row, inferior glide, seated press-up, body-lifting). Healthy, physically active adults (18-40 y; Tegner ≥5) will perform three repetitions per exercise with metronome-paced phases (≈3 s concentric, 3 s isometric, 3 s eccentric), 5-s rest between repetitions and 2-min between exercises; load will be individualized to reach OMNI RPE 6-8. Surface EMG (TeleMyo DTS; Noraxon) will be recorded from the latissimus dorsi (medial and lateral) and selected synergists (teres major, infraspinatus, posterior deltoid, triceps); electrode placement will follow SENIAM recommendations. Signals will be band-pass filtered (20-500 Hz), rectified, RMS-smoothed with a 100-ms window, and normalized to %MVIC using standardized MVC tests; exercise/MVC order will be randomized to limit bias. The primary outcome is mean normalized EMG amplitude per exercise; secondary outcomes include peak amplitude and categorical activation levels (low ≤20% MVIC, moderate 21-40%, high 41-60%, very high >60%). The study involves minimal risk (possible mild skin irritation under electrodes and transient post-exercise fatigue).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The latissimus dorsi (LD) originates from the spinous processes of the lower six thoracic vertebrae and the thoracolumbar fascia/iliac crest, and-together with the teres major-attaches to the medial lip of the intertubercular groove of the humerus. Functionally, LD contributes to shoulder adduction, internal rotation, and extension, linking the upper limb to the trunk. Alongside the rotator cuff, prevention of superior translation of the humeral head may be provided by the glenohumeral adductors (pectoralis major and LD) acting as humeral head depressors via a medio-inferior vector created by their tendon orientation. From an osteokinematic perspective, LD may protect against subacromial pain by facilitating inferior glide of the humeral head on the glenoid.

Selecting an appropriate strengthening exercise is critical to restore muscle performance and functional arm elevation in patients with shoulder injury or dysfunction. The literature emphasizes exercises targeting activation of the rotator cuff and scapulothoracic muscles that contribute to functional elevation. Surface electromyography (sEMG) is commonly used to guide exercise selection and progression by quantifying a muscle's contribution across different exercises, thereby enabling evidence-based advancement in strengthening programs.

However, much of the existing LD literature centers on lateral pull-down variations, with limited data for rehabilitation-relevant tasks such as low row, inferior glide, bent-over row (with trunk flexion), seated press-up, and body-lifting. Focusing on a single exercise limits clinical decision-making for shoulder rehabilitation (exercise selection and progression). Therefore, to support a scientific, evidence-based progression for LD strengthening in rehabilitation, this study was planned to obtain comprehensive sEMG data across multiple exercises.

Aim: To examine LD EMG activation levels during different exercises and determine between-exercise differences.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Altındag
      • Ankara, Altındag, Turkey (Türkiye), 06100
        • Recruiting
        • Hacettepe University
        • Contact:
        • Sub-Investigator:
          • Gizem Soylu, MSc
        • Sub-Investigator:
          • Kubra Caylan Gurses, MSc
        • Sub-Investigator:
          • Ceyda Sevinc, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Healthy, physically active adults aged 18-40 years. Eligibility requires Tegner ≥5, full glenohumeral range of motion, no shoulder/cervical/lumbar complaints in the past 6 months, and no systemic or neurological disease.

Description

Inclusion Criteria:

  • Age 18-40 years
  • No range-of-motion restriction at the glenohumeral joint
  • No shoulder, cervical, or lumbar region complaints/injury within the past 6 months
  • No systemic or neurological disease
  • Competent to consent and provides written informed consent
  • Tegner Activity Scale ≥ 5

Exclusion Criteria:

  • Body mass index (BMI) > 25 kg/m²

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Healthy adults
Single-visit laboratory cohort. Physically active adults perform exercises; surface EMG is recorded from the latissimus dorsi
Behavioral: Exercise
Participants will perform six standardized pulling tasks-inferior glide, low row, seated row, bent-over row, seated press-up, and body lifting-using a resistance band or body weight. Each exercise is done for 3 repetitions with ~5 s between reps and ~2 min between exercises. Resisted exercises follow a metronome-paced 3 s concentric / 3 s isometric / 3 s eccentric tempo; purely isometric tasks are held for 3 s. Load is individualized with the OMNI 0-10 scale and increased during up to 10 familiarization reps until perceived exertion reaches 6-8/10. Exercise order is randomized to minimize ordering effects.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Electromyography
Time Frame: Baseline (Day 1)
Surface EMG from the latissimus dorsi (medial and lateral sites) will be recorded with an 8-channel system (TeleMyo DTS; Noraxon). Skin will be shaved and cleaned with 70% isopropyl alcohol; bipolar Ag/AgCl electrodes will be placed per SENIAM with a 2 cm inter-electrode distance (MLD ~lateral to T9; LLD ~4 cm inferior to the scapular inferior angle, midway between the spine and lateral trunk). A synchronized video (Logitech C920) will mark movement onset/offset and will be deleted after analysis (no copies kept). Signals will be normalized to %MVIC using three 5-s MVIC trials (30-s rest between trials; ~2-min between muscles) performed in standardized positions with verbal encouragement. The outcome is the mean %MVIC during the steady phase of each exercise.
Baseline (Day 1)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Electromyography-Other muscles
Time Frame: Baseline (Day 1)
Surface EMG will also be recorded from teres major, infraspinatus, posterior deltoid, and triceps using the same preparation, SENIAM-based placement, and processing/normalization procedures described above. The outcome is the mean normalized EMG amplitude (%MVIC) during the steady phase of each exercise (isometric: central 3-s window; resisted: concentric 3 sec -isometric 3 sec- eccentric 3 sec).
Baseline (Day 1)
Activity Level
Time Frame: Baseline (Day 1)
Baseline physical activity will be characterized using the Tegner Activity Scale (0-10) prior to testing; higher scores indicate greater habitual activity.
Baseline (Day 1)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Hacettepe University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 12, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 25, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 25, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 9, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 9, 2025

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 22, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
December 29, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 22, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
December 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • LDORSI-EMG

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

No individual participant data (IPD) will be shared. De-identified aggregate results will be disseminated in publications. The dataset includes physiological signals; synchronized videos are deleted after analysis.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Muscle Activation

Clinical Trials on Exercise

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings